Casinvent

CasInvent Pharma, a.s. is a pioneering biotech startup focused on developing highly potent and selective inhibitors of CK1 kinases for the treatment of various cancers, including leukaemias, lymphomas, and solid tumors. The company operates in the pharmaceutical and biotechnology market, primarily serving healthcare providers, research institutions, and pharmaceutical companies. CasInvent Pharma's business model revolves around the research and development of novel therapeutic compounds, which are then licensed to larger pharmaceutical firms for further development and commercialization. This model allows the company to generate revenue through licensing fees, milestone payments, and royalties on sales of the developed drugs.

To date, CasInvent Pharma has prepared and tested over 250 compounds, demonstrating significant progress in targeting CK1 and CK2 kinases, which play crucial roles in neurodegenerative diseases and various cancers. The company's innovative approach has garnered recognition, including the prestigious Neuron Award for excellent Technology Transfer.

CasInvent Pharma's commitment to advancing cancer treatment is further evidenced by its focus on addressing unmet medical needs and improving patient outcomes. By leveraging cutting-edge research and strategic partnerships, the company aims to bring new, effective cancer therapies to market.

Keywords: CK1 kinases, cancer treatment, leukaemias, lymphomas, solid tumors, biotech startup, pharmaceutical R&D, licensing, neurodegenerative diseases, innovative inhibitors.